Splicing Patterns in SF3B1 -Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes

Archive ouverte

Bigot, Jeremy | Lalanne, Ana | Lucibello, Francesca | Gueguen, Paul | Houy, Alexandre | Dayot, Stephane | Ganier, Olivier | Gilet, Jules | Tosello, Jimena | Nemati, Fariba | Pierron, Gaelle | Waterfall, Joshua | Barnhill, Raymond | Gardrat, Sophie | Piperno-Neumann, Sophie | Popova, Tatiana | Masson, Vanessa | Loew, Damarys | Mariani, Pascale | Cassoux, Nathalie | Amigorena, Sebastian | Rodrigues, Manuel | Alsafadi, Samar | Stern, Marc-Henri | Lantz, Olivier

Edité par CCSD ; American Association for Cancer Research -

International audience. Abstract Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors represents a potential source of tumor neoantigens, which would be both public (shared between patients) and tumor-specific (not expressed in normal tissues). In this study, we show that mutations of the splicing factor SF3B1 in uveal melanoma generate such immunogenic neoantigens. Memory CD8+ T cells specific for these neoantigens are preferentially found in 20% of patients with uveal melanoma bearing SF3B1-mutated tumors. Single-cell analyses of neoepitope-specific T cells from the blood identified large clonal T-cell expansions, with distinct effector transcription patterns. Some of these expanded T-cell receptors are also present in the corresponding tumors. CD8+ T-cell clones specific for the neoepitopes specifically recognize and kill SF3B1-mutated tumor cells, supporting the use of this new family of neoantigens as therapeutic targets. Significance: Mutations of the splicing factor SF3B1 in uveal melanoma generate shared neoantigens that are uniquely expressed by tumor cells, leading to recognition and killing by specific CD8 T cells. Mutations in splicing factors can be sources of new therapeutic strategies applicable to diverse tumors. This article is highlighted in the In This Issue feature, p. 1861

Consulter en ligne

Suggestions

Du même auteur

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.

Archive ouverte | Saint-Ghislain, Mathilde | CCSD

International audience. BackgroundMBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Altho...

Association of Partial Chromosome 3 Deletion in Uveal Melanomas With Metastasis-Free Survival

Archive ouverte | Rodrigues, Manuel | CCSD

International audience. Importance: Studies on uveal melanomas (UMs) have demonstrated the prognostic value of 8q gain and monosomy 3, but the prognosis of UMs with partial deletion of chromosome 3 remains to be def...

Germline MBD4 Mutations and Predisposition to Uveal Melanoma

Archive ouverte | Derrien, Anne-Céline | CCSD

International audience. Background: Uveal melanoma (UM) arises from malignant transformation of melanocytes in the uveal tract of the eye. This rare tumor has a poor outcome with frequent chemo-resistant liver metas...

Chargement des enrichissements...